Author information

¹Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, Madrid, Spain; Health Research Institute Gregorio Marañón (IiSGM), Madrid, Spain; Centre for Biomedical Research, Network on Liver and Digestive Diseases (CIBEREHD), Madrid, Spain.

²Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, Madrid, Spain; Health Research Institute Gregorio Marañón (IiSGM), Madrid, Spain; Centre for Biomedical Research, Network on Liver and Digestive Diseases (CIBEREHD), Madrid, Spain. Electronic address: fcubero@ucm.es.

Abstract

The study by Hirschfield et al.¹ demonstrated safety profile and clinically significant effectiveness of the peroxisome proliferator-activated receptor delta (PPARδ) agonist seladelpar in patients with primary biliary cholangitis, highlighting its plausible use as a second-line treatment to reduce disease activity and pruritus.